Kyorin Set To Transfer To Japanese Joint Venture
A joint venture agreement has been executed that will see Daito Pharmaceutical, Meiji Seika Pharma and the Development Bank of Japan create an entity to take control of Kyorin Pharmaceutical’s generic drug business in Japan.
Generics Bulletin - October 9, 2026

Winter Is Coming, But Will It Bring A Bumper Cold & Flu Season?
Outlooks in the US and Europe suggest a middling illness season is on the way following an Australian winter that was no worse than average. Consumer health companies hoping for a stronger season to provide a much needed shot in the arm to cold and flu product sales may be left disappointed.
HBW Insight - October 9, 2026

Sandoz Sees Reversal As Appeals Court Finds United Therapeutics Remodulin Restriction Procompetitive
United Therapeutics has won on antitrust grounds at the Third Circuit, with the court finding its Remodulin cartridge exclusivity was procompetitive despite acknowledging the firm "understood – and even desired" the restrictions would hinder Sandoz's generic launch.
Generics Bulletin - October 9, 2026

How Spain Can Build Up Its Burgeoning Biotech Businesses
Asabys co-founder Clara Campàs gives Scrip an investor’s insight into the country’s future prospects in scaling up the sector and her preference for a pan-European approach.
Scrip - October 9, 2026

AESGP Switch Day: France Plans Reclassifications Without Company Applications
French self-care industry association NèreS welcomes a move that would let regulator ANSM review a medicine’s prescription status on its own initiative or at ministers’ request, taking into account its status elsewhere in Europe.
HBW Insight - October 9, 2026

Viatris Veers Further Towards Innovation With $1.65bn Pacira Buyout
Viatris has taken another step towards innovative higher-margin products through a $1.65bn purchase of Pacira BioSciences. The firm will gain access to pain products that are expected to be complementary to its filed fast-acting meloxicam candidate.
Scrip - October 9, 2026

Value Added: Viatris Spotlights 505(b)(2) Assets As It Shells Out $1.65bn For Pacira
Marking another step in its push towards innovative higher-margin products, Viatris has agreed to pay $1.65bn for Pacira BioSciences, gaining access to its 505(b)(2) non-opioid pain products Exparel and Zilretta that are expected to be complementary to Viatris’ filed fast-acting meloxicam candidate.
Generics Bulletin - October 9, 2026

Moderna-Merck’s Intismeran Exposes The Personalized Medicine Infrastructure Gap
Moderna and Merck's individualized neoantigen therapy intismeran autogene has put personalized mRNA cancer treatment on the path to market. At LSX USA, panelists cautioned that manufacturing, diagnostics, regulation and reimbursement may not be ready.
In Vivo - October 9, 2026

FDA Clears Motivista For Schizophrenia’s Negative Symptoms, But Coverage Remains Unsettled
FDA cleared Click Therapeutics’ Motivista, a smartphone adjunct for schizophrenia’s negative symptoms. Click says state Medicaid comes first, but the trial gain was modest and Medicare eligibility is unresolved as it readies a launch without Boehringer Ingelheim.
Medtech Insight - October 9, 2026

BioJapan: Policy Changes Key To Rebuilding Japan’s Competitiveness
A range of speakers from government, regulators and the industry lay out at the BioJapan meeting in Yokohama the major challenges facing Japan's biopharma sector as it looks to regain its competitiveness on the world stage.
Scrip - October 9, 2026